Levocarnitine

Educational overview

Prescription products treat defined carnitine deficiencies; general energy or weight-loss use is off-label. IV hypersensitivity and seizures are reported.

Levocarnitine is the pharmaceutical name for L-carnitine, a naturally occurring quaternary amine synthesised in the liver and kidney from lysine and methionine and concentrated in skeletal and cardiac muscle. Its physiological role is to shuttle long-chain fatty acids across the inner mitochondrial membrane so they can be oxidised for energy, and to buffer acyl groups. Because most people synthesise enough and obtain more from meat and dairy, it is not classed as an essential nutrient. It exists as a prescription medicine for defined carnitine-deficiency states and, separately, as a dietary supplement in L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine forms marketed for energy, exercise performance and fat loss.

Evidence for the prescription indications comes from clinical studies of inherited disorders of fatty-acid metabolism and of end-stage renal disease, where dialysis removes carnitine and replacement corrects measurable deficiency. Evidence for weight loss in the general population is weaker: a 2016 meta-analysis of nine randomised trials in 911 adults and a 2020 meta-analysis of 37 trials in 2292 adults, both by Iranian nutrition groups, found a statistically significant but modest reduction in body weight of roughly one kilogram, with the effect fading over longer durations and confined to people with overweight or obesity. Trials for athletic performance, male infertility and cardiovascular outcomes are mixed, and the NIH Office of Dietary Supplements summarises them as inconclusive.

In the United States levocarnitine is FDA-approved as Carnitor and generics in oral tablet, oral solution and intravenous forms for primary systemic carnitine deficiency, certain secondary deficiencies from inborn errors of metabolism, and dialysis-related deficiency. Any use for weight management, energy or general wellness is off-label, and injectable products sold by wellness clinics, alone or inside MIC lipotropic blends, are compounded rather than approved products; a 2015 FDA alert about unapproved Sunshine Labs injectables included an L-carnitine injection. In Europe and Australia prescription carnitine is likewise limited to deficiency indications, while oral supplements are regulated as foods. The label lists hypersensitivity reactions with intravenous use and seizures in people with or without prior seizure disorders.

Prescription oral and injectable products carry manufacturer storage instructions on the label, typically room temperature protected from light, with single-dose vials discarded after opening; compounded injectables instead carry the pharmacy's beyond-use date. Supplement capsules and liquids follow the product label and are regulated as foods, so potency and purity are not verified before sale. Because the same name covers a prescription drug, a compounded injectable and a supplement, an inventory record is only informative if it captures the form, salt, concentration or strength, manufacturer or pharmacy, and lot number. A dose log entry that records the route alongside the product identity distinguishes an intravenous replacement dose from an oral supplement, which otherwise look identical on paper.

Category

Amino-acid derivative / metabolic

Routes represented

Oral / Other / unspecified

Storage context

Follow the product or pharmacy label; requirements vary by route and formulation.